StreetAlpha.app
Home › Stocks › AVXL

Anavex Life Sciences Corp. (AVXL)

$0.59
▼ −11.39%
LAST CLOSE · NOV 20

Anavex Life Sciences is a New York biopharmaceutical company developing drug candidates for Alzheimer's and other brain diseases. It last closed at $0.59 on Nov 20, down 11.39% on the day. The next earnings report for AVXL is expected around Tue, Nov 24, 2026. For the quarter ended Jun 2026, AVXL reported EPS of $0.08. Over its last 5 reports the stock moved an average of 6.7% the session after earnings.

AI Auto Pilots
Is AVXL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AVXL.

Key Stats

Last 12 months
Results
Net income
−$13.0M
EPS (diluted)
−$0.14
Valuation
Market cap
$54.8M
92.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$118.3M
At Jun 30
Shareholder equity
$112.4M
Shares outstanding
92.7M
At Aug 28
Fiscal year endsSeptember
ExchangeNasdaq
Financials history
FY2021: −$37.9M−$37.9MFY2021FY2022: −$48.0M−$48.0MFY2022FY2023: −$47.5M−$47.5MFY2023FY2024: −$43.0M−$43.0MFY2024FY2025: −$46.4M−$46.4MFY2025

From AVXL's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 28). Last 12 months adds up the four latest quarters.

Next report
Nov 24
Estimated date · Time not announced
Reported EPS
$0.08
Quarter ended Jun 2026
Year ago EPS
-$0.16
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Sep 2024: -$0.14Sep '24Dec 2024: -$0.14Dec '24Mar 2025: -$0.13Mar '25Jun 2025: -$0.16Jun '25Sep 2025: -$0.11Sep '25Dec 2025: -$0.06Dec '25Mar 2026: -$0.06Mar '26Jun 2026: $0.08Jun '26Latest $0.08
Revenue by quarter
Not enough quarters on file yet.
How AVXL moved after its last 5 reports
Average move the session after a report ±6.7%
Jul 30, 2026Time not announced+8.4%
Feb 9, 2026Time not announced+6.1%
Nov 25, 2025Time not announced+12.3%
May 9, 2024Time not announced+4.6%
Dec 28, 2020After the close−2.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AVXLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Technical Analysis

AVXL · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 78% below its 20 day and 162% below its 50 day average. It is 374% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 17), oversold. The nearest support is the 52 week low at $0.59, and the nearest resistance the Pivot at $0.63.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 17.9%/day
Key levels
$5.3652 week high+808.5%
$2.81200 day average+376.3%
$2.21100 day average+274.6%
$1.5550 day average+162.7%
$1.32Swing high (Oct 29)+123.7%
$1.0620 day average+79.7%
$0.67Pivot R1+13.6%
$0.63Pivot+6.8%
$0.5952 week low+0.0%
$0.59Last close
$0.55Pivot S1−6.8%
Indicators
RSI (14)17.16Oversold below 30Oversold
MACD-0.25Below its signal lineBearish
Stochastic1.1Near the bottom of its rangeOversold
ADX (14)57.9Strong downtrend
Williams %R-99.8Oversold below −80, overbought above −20Oversold
CCI (20)-158.5Oversold below −100, overbought above 100Oversold
Rate of change−48.6%Change over 10 sessionsBearish
ATR (14)$0.11Typical daily range, 17.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AVXL

What happened before

See how AVXL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AVXL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AVXL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AVXLHow many large options trades hit AVXL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AVXL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼57 buying vs 97 selling
  • ▲Held by funds +2.6 pts
  • ▼Funds holding -14
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding167181−7.7%
In funds' top 1000–
Held by funds42.6%40.0%+2.6 pts
New / increased14 / 4323 / 64−34.5%
Reduced / sold out71 / 2655 / 32+11.5%
Put/call ratio0.020.00+1983.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AVXL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVXL is in one of them and how their past AVXL trades turned out.

AVXL in the AI portfolios
Loading…

AVXL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AVXL in an article yet. Here's the latest on the wider market.

AVXL in the news

AVXL Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jan 20
Who traded AVXL · since 2022
Latest 2 filings
$1K – $15KTraded Dec 12, 2022Filed Jan 20, 2023
$1K – $15KTraded Oct 12, 2022Filed Nov 16, 2022
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYSell$1K – $15KDec 12, 2022Jan 20, 202339 d
Christopher JacobsR · NYBuy$1K – $15KOct 12, 2022Nov 16, 202235 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Anavex Life Sciences

Anavex Life Sciences is a clinical stage biopharmaceutical company based in New York. It develops drug candidates for diseases of the central nervous system, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome and other rare brain disorders. Its main candidate, blarcamesine, is being studied as an oral treatment that acts on the sigma receptor. The company's intended customers are patients with these conditions and the healthcare providers who treat them.

Headquarters
New York, NY